Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate ALN-AGT01 in Patients With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Has mild to moderate hypertension with mean sitting systolic blood pressure (SBP) of \>130 and ≤165 mmHg without hypertensive medication for Parts A, B and D, and \>135 and ≤165 mmHg without hypertensive medication for Part E~* Parts A and B: Has body mass index (BMI) ≥18 and ≤35 kg/m\^2; Part D: Has BMI \>35 and ≤50 kg/m\^2; Part E: Has BMI ≥18 kg/m\^2 and ≤50 kg/m\^2~* Has a normal 12-lead electrocardiogram (ECG)~* Is a nonsmoker~Exclusion Criteria:~* Has secondary hypertension~* Has orthostatic hypotension~* Has estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73m\^2~* Recently received an investigational agent~* Has diabetes mellitus~* Has history of any cardiovascular event~* Has history of intolerance to SC injection(s)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Part A: SAD: ALN-AGT01 (Type: EXPERIMENTAL): Participants will be administered a single dose of ALN-AGT01.
- Part A: SAD: ALN-AGT01-Matching Placebo (Type: PLACEBO_COMPARATOR): Participants will be administered a single dose of ALN-AGT01-matching placebo.
- Part B: SD: ALN-AGT01 (Type: EXPERIMENTAL): Participants with controlled salt intake will be administered a single dose of ALN-AGT01.
- Part B: SD: ALN-AGT01-Matching Placebo (Type: PLACEBO_COMPARATOR): Participants with controlled salt intake will be administered a single dose of ALN-AGT01-matching placebo.
- Part D: MD: ALN-AGT01 + Irbesartan-Matching Placebo (Type: EXPERIMENTAL): Participants, who are obese, will be administered multiple doses of ALN-AGT01 and irbesartan-matching placebo.
- Part D: MD: ALN-AGT01-Matching Placebo + Irbesartan (Type: ACTIVE_COMPARATOR): Participants, who are obese, will be administered multiple doses of ALN-AGT01-matching placebo and irbesartan.
- Part E: Open Label: ALN-AGT01 + Irbesartan (Type: EXPERIMENTAL): Participants will be administered a single dose of ALN-AGT01 and multiple doses of irbesartan.

Based on this trial design, predict the completion outcome and termination type (if applicable).